

References

I-56

1. Manuck T, Watkins W, Moore B, et al. Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention. *American Journal of Obstet Gynecol.* 2014; 210(4):1-321.
2. Senat M, Porcher R, Winer N et al. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. *Am J Obstet Gynecol.* 2013; 208(3)194:1-8.
3. Romero R, Yeo L, Chaemsaitong P, Chaiworapongsa T, Hassan S. Progesterone to prevent spontaneous preterm birth. *Semin Fetal Neonatal Med.* 2014;19(1)15-26.
4. Alfirevic Z, Owen J, Carreras E, et al. Vaginal progesterone, cerclage or cervical pessary for preventing preterm birth in asymptomatic singleton pregnant women with a history of preterm birth and a sonographic short cervix. *Ultrasound Obstet Gynecol.* 2013;41:146–151.
5. Rouholamin S, Elahe Z, Laleh Si. Evaluation the Effect of 17-Alpha Hydroxyprogesterone Caproate on Gestational Diabetes Mellitus in Pregnant Women at Risk for Preterm Birth. *Adv Biomed Res.* 2015;4:242.
6. Bafghi A, Bahrami E ,and Leila Sekhvat. Comparative Study of Vaginal versus Intramuscular Progesterone in the Prevention of Preterm Delivery: A Randomized Clinical Trial. *Electronic Physician.* 2015;7.6:1301–1309.
7. Society for Maternal Fetal Medicine. The Choice of Progestogen for the Prevention of Preterm Birth in Women with Singleton Pregnancy and Prior Preterm Birth. *Am J Obstet Gyencol.* 2017;216(3):B11-B13.
8. Rundell K & Panchal B. Preterm Labor: Prevention and Management. *Am Fam Physician.* 2017; 95(6):366-372.